The search for an effective HIV-1 vaccine has been frustratingly long, with a limited number of promising approaches in the pipeline. The use of live attenuated
M A J O R A R T I C L E
Highly Attenuated Rabies Virus-Based Vaccine Vectors Expressing Simian-Human Immunodeficiency Virus 89.6P Env and Simian Immunodeficiency Virus mac239 Gag Are Safe in Rhesus Macaques and Protect from an AIDS-Like Disease simian immunodeficiency virus (SIV), which provided complete protection from challenge with homologous wild-type strains, indicates the potential feasibility of live viral vectors as HIV-1 vaccines (for a review, see [1] ). As replicating immunogens, such vectors are capable of eliciting immune responses and of providing protection from infection, which is not seen with other approaches based on DNA or nonreplicating vectors.
For HIV-1 and SIV, there is evidence that virus-specific CD8 + cytotoxic T lymphocytes (CTLs) play an important role in controlling viral replication and disease progression [2] . In nonhuman primates, studies based on DNA vaccines and recombinant viral vectors have shown the capacity to elicit virus-specific CTLs. Upon pathogenic simian-human immunodeficiency virus (SHIV) or SIV challenge, vaccinated macaques ex- perienced reduced peak viral loads and a delayed course of disease progression [3] [4] [5] . However, other studies of CTL-based vaccines reported only transient control of viral replication after pathogenic SIV mac239 challenge [6] and viral escape of immune control through mutations in CTL epitopes (reviewed in [7] ). The role of antibodies in conferring protection to HIV-1 infection has been examined in adoptive transfer experiments in which the passive immunization of HIV-1 neutralizing antibodies was able to prevent either infection or disease in both chimpanzee and rhesus macaque challenge models [8] . Also in macaques, topical application of a broadly neutralizing antibody was shown to block the vaginal transmission of a SHIV virus [9] . Thus, it seems likely that a successful HIV-1 vaccine should be able to activate both arms of the immune system.
Rabies virus is a member of the family Rhabdoviridae of nonsegmented, single-stranded, negative-sense RNA viruses. Expression of HIV-1 and other viral antigens from attenuated, recombinant rabies virus has been shown to be safe and to induce both humoral and cellular immune response in smallanimal models [10] [11] [12] [13] . Although immune responses generated in rodent models are not always predictive of a potential HIV-1 vaccine, the basic parameters of the anti-HIV-1 response can be studied in such systems.
We performed a proof-of-principle experiment in nonhuman primates with rabies virus vectors expressing SHIV 89.6P Env and SIV mac239 Gag. The vectors are based on a replication-competent rabies virus vaccine strain, SAD B19, that has been used for the oral immunization of wild animals in Europe for 120 years [14] . However, because of residual vector pathogenicity after nonperipheral inoculation [15] , we introduced a previously described mutation in rabies virus glycoprotein G (rabies virus-G) to abolish its neurotropic character [16, 17] . In mice, rabies viruses carrying this mutation are apathogenic even after direct intracranial inoculation [17] .
MATERIALS AND METHODS

Recombinant Vaccine Vectors
The recombinant rabies virus cDNA pSPBN-333 has been described elsewhere [17] . pSPBN-IG was constructed by polymerase chain reaction amplification of the chimeric vesicular stomatitis virus (VSV)/rabies virus-G containing the ectodomain and transmembrane domain from VSV strain Indiana, and the cytoplasmic domain (CD) of rabies virus-G from pSN-VSV-G [18] , which was used to replace the rabies virus-G in pSPBN-333, resulting in pSPBN-IG. SIV mac239 Gag or SHIV 89.6P Env containing the rabies virus CD were amplified from p239SpSp5 [19] or pDG-89.6P-RVG [20] , respectively, and cloned into SPBN-333 or SPBN-IG. The plasmids were designated pSPBN-333-89.6P, pSPBN-333-SIV Gag, pSPBN-IG-89.6P, and pSPBN-IG-SIV Gag. Sequences were confirmed by DNA sequencing, and infectious viruses SPBN-333, SPBN-IG, SPBN-333-89.6P, SPBN-333-SIV Gag, SPBN-IG-89.6P, and SPBN-IG-SIV Gag were recovered using standard methods [12] .
Macaque Studies
Six adult male rhesus macaques (Macaca mulatta) were used in the study. They were screened and confirmed to be free of antibodies to SIV, simian retrovirus, simian T cell leukemia virus type 1, isolatable SIV before their inclusion in the study. The macaques were housed at the Southern Research Institute (Frederick, MD) in accordance with American Association for Accreditation of Laboratory Animal Care standards. The experimental design met full approval of the institute's Animal Care and Use Committee.
Vaccinations
On study day 0, 4 test macaques (3413-3416) were immunized by intramuscular (im) inoculation with foci-forming 
SHIV 89.6P Challenge
Four months after the boost with vectors containing VSV-G, all macaques were challenged intravenously (iv) with 50 monkey infectious doses (MID) of pathogenic SHIV 89.6P . The SHIV 89.6P challenge stock has been described elsewhere [21] [22] [23] and was provided by Dr. N. Letvin (Harvard University, Cambridge, MA).
Immune Assays
Oligomeric gp140 ELISA. The oligomeric gp140 ELISA was performed essentially as described elsewhere [24] , except that plates were coated with recombinant vaccinia virus-derived oligomeric gp140 of strain 89.6P (J.P.M., unpublished data). Background was defined as the average signal at each dilution for control macaques and a positive signal as at least twice background levels.
Virus neutralization assays. The rabies virus neutralizing antibody titers were determined using the CVS-11 reference strain, as described elsewhere [25] . The virus neutralizing antibody titers were transformed into international units using the World Health Organization's anti-rabies virus antibody standard. To determine levels of VSV neutralizing antibodies, we modified the rabies virus neutralization assay by replacing the CVS-11 strain with the SPBN-IG virus. Neutralization titers were determined as the serum dilution that achieved 50% reduction of foci-forming units of input virus.
HIV-1/SIV/SHIV neutralization assay were performed as described elsewhere [26] . Neutralization was measured as a function of reductions in luciferase reporter gene expression after a single round of infection in TZM-bl cells (ARRRP) [26] . Assay stocks of SHIV-89.6 and SHIV-89.6P were prepared in human peripheral blood mononuclear cells (PBMCs).
Cellular responses. Enzyme-linked immunospot (ELISpot) assays for specific cellular immune responses to SIV mac239 Gag and SHIV 89.6P Env were performed as described elsewhere [27] . Background levels were determined by counts in medium-only control, and the criteria for a positive signal were levels at least 2 times background and at least 55 sfu/10 6 PBMCs. Viral load determinations. SIV viral RNA was quantitated as described elsewhere [28, 29] , with the following modifications: Gag primers were SIV forward 5 -AGTATGGGCAGCAA-ATGAAT-3 and SIV reverse 5 -TTCTCTTCTGCGTGAATGC-3 , and the probe was SIV 6FAM-AGAT-TTGGATTAGCAGAA-AGCCTGTTGGA-TAMRA. The assay has a threshold sensitivity of 200 RNA copies/mL of plasma, with interassay variations averaging 0.5 log 10 .
RESULTS
Vaccination schedule. Six Mamu-A*01 major histocompatibility complex (MHC) class I allele-negative rhesus macaques (Macaca mulatta) were inoculated with the constructs shown in figure 1B. Four macaques (3413, 3414, 3415, and 3416) were vaccinated with vectors expressing 89.6P Env and SIV 239 Gag according to the schedule described in figure 1A and Materials and Methods. Two macaques (3417 and 3418) were vaccinated with vectors not expressing transgenes (SPBN-333 and SPBN-IG; figure 1B) . Expression of 89.6P Env, SIV Gag, rabies virus-G, and VSV-G proteins from respective viral vectors was confirmed by indirect immune fluorescence ( figure 1C) .
Humoral immune response to vaccine antigens. After each vaccination with vectors containing rabies virus-G or VSV-G, we analyzed the humoral immune response to vaccine antigens. Four and 8 weeks after the initial inoculation, 4 weeks after the inl boost at week 45, and 4 weeks after the im boost at week 55, serum from all macaques was analyzed in an oligomeric gp140 ELISA assay [20] for seroconversion to 89.6P Env. As seen in figure 2A , 2 of 4 test macaques (3413 and 3416) seroconverted against 89.6P Env by 4 weeks after the initial inoculation. By week 8, macaque 3414 was also positive, and the response in macaque 3415 was just below the positive response cutoff of twice the average background signal seen in the controls. The week 45 inl boost appeared to have no effect, as is seen in the week 49 results. However, the im boost at week 55 did elicit a response, in that all 4 test macaques were positive at week 59, with the highest increase in signal seen in macaques 3415 and 3416. This modest boost is likely attributable to the presence of 89.6P Env on the rabies virus particle. Inclusion of the rabies virus-G cytoplasmic domain on the 89.6P Env allows efficient incorporation of the chimeric protein into the rabies particle [30] . Serum from the designated time points was analyzed for HIV-1 neutralizing antibodies; however, no neutralizing antibodies were detected (data not shown).
We also assessed the anti-rabies virus-G response in all macaques. Figure 2B shows that the initial inoculation elicited high-titer rabies virus neutralizing antibodies, in the range of 20.5-116.5 IU, which persisted throughout the course of the study. For reference, 0.5 IU is considered to be protective against classic rabies infection in both humans and animals. The inl boost at week 45 had only a small effect on the antirabies virus response, whereas the im boost at week 55 raised the already high titers of anti-rabies virus antibodies ( figure  2B ). The inl boost with rabies was based on the finding for vaccinia virus that overcoming preexisting immunity can be achieved by mucosal immunization [31] . However, this seems not to be the case for rabies virus, and effective boosting of the anti-rabies virus-G and anti-Env response was not observed. The im boost was administered to determine whether the Env and Gag antigens contained within the rabies vector could enhance the SHIV-specific response. The increases in anti-Env and anti-G antibodies seen after the im inoculation were most likely due to Env and rabies virus G proteins contained in virions. The lack of detectable cellular responses indicates that no viral replication occurred.
The above findings led to the development of the SPBN-IG (VSV-G expressing) vectors (figure 1B). With these new vectors, we sought to augment the anti-Env and anti-Gag response by infecting with a vector expressing a different membrane glycoprotein. Previous work showed that rhabdoviral glycoprotein G can efficiently be substituted by other viral and cellular glycoproteins [18, 32, 33] . Foley et al. [18] showed that a rabies virus containing the VSV G protein grew similarly to rabies but failed to protect mice from challenge with a pathogenic rabies virus, which indicates that a rabies virus vaccine vector with a VSV G protein should be able to infect in the presence of high-titer anti-rabies virus antibodies. On week 120, all macaques were boosted im with SPBN-IG 89.6P Env and SPBN-IG SIV Gag (test macaques) or SPBN-IG (control macaques). As displayed in figure 2C , anti-VSV-G antibodies were absent in all macaques at the time of boosting. However, after the boost, all macaques seroconverted against VSV-G and raised high titers of VSV neutralizing antibodies ( figure 2C) . The strong immune response to the SPBN-IG vectors shows that we were able to successfully infect all macaques and thereby circumvent the rabies virus neutralizing antibodies. We tested post-SPBN-IG boost serum for HIV-1 neutralizing antibodies, but only very low level or undetectable responses were seen (data not shown).
Cellular immune response. We assessed the anti HIV/SIV cellular immune response by interferon (IFN)-g ELISpot assay.
PBMCs from all macaques were tested against overlapping peptide pools spanning the entirety of 89.6P Env and SIV Gag for the presence of IFN-g-secreting cells. At no point before the SPBN-IG boost did we detect any Env-or Gag-specific cellular immune responses (data not shown). This lack of cellular responses is in line with our observation with rabies virus vectors in mice, where cellular responses were very low after vaccination but were robust after challenge with recombinant vaccinia virus expressing the same HIV-1 or SIV antigen [11] [12] [13] 34] . However, after the SPBN-IG boost, we were able to detect 89.6P Env-and SIV Gag-specific IFN-g-secreting cells ( figure 3 ). Responses in 3 of 4 test macaques peaked 4 weeks after boost, with macaque 3413 responding to epitopes in SIV Gag and both Env pools tested and macaques 3414 and 3415 primarily responding to epitopes in the N-terminal half of 89.6P Env (89.6P Env 1; figure 3 ). The results of the ELISPOT assay for macaque 3416 are not shown, because this macaque had high numbers of IFN-g-secreting cells throughout the study (1000-5000 cells/10 6 PBMCs), even after restimulation with medium only. Because the observed responses were at least as potent as those seen in other vaccine approaches using this rhesus macaque model system [35, 36] , all macaques were challenged iv 4 months after the SPBN-IG boost with 50 MID of pathogenic SHIV 89.6P .
Post-SHIV 89.6P challenge analysis. After challenge, we continued to monitor the HIV/SIV-specific immune responses, and we also determined SHIV 89.6P loads, CD4 + T cell counts, and clinical events in all macaques. The immunogenicity results presented in figure 4 indicate that rabies virus-based vectors were able to efficiently prime both arms of the immune system. In the case of SHIV antigen-specific T cell responses, all vaccinated macaques showed a high level of SIV Gag-and 89.6P Env-specific T cells in the IFN-g ELISpot assay, with the largest expansion of SHIV-specific T cells at week 4 after infection (figure 4E). One control macaque (3417) did not mount any Gag-or Env-specific cellular immune response, and the other macaque (3418) had only transient responses at 8 weeks after challenge. Postchallenge serum was assayed for virus neutralizing antibodies against SHIV IIIB , SHIV 89.6 (figure 4C), and SHIV 89.6P ( figure 4D ). All 4 vaccinated macaques developed virus neutralizing antibodies against SHIV 89.6P , with high titers of antibodies seen in macaques 3414 and 3415. More modest responses were generated against strain 89.6. By week 4 after challenge, macaques 3415 and 3416 had anti-89.6 titers 11:100, and, by week 20, macaque 3414 had an anti-89.6 titer of 1: 287. In the control macaques, we detected levels of virus neutralizing antibodies against SHIV 89.6 or 89.6P only close to baseline levels ( figure 4C and 4D ). Not surprisingly, no neutralizing antibodies were detected against SHIV-IIIB in any of the 6 macaques [37] . Protection by these observed cellular and humoral immune responses against an AIDS-like disease in the vaccinated macaques was indicated by all 4 macaques controlling the infection well during the 20 weeks of follow-up. All macaques had similar peak viral loads of ∼10 7 copies/mL 2 weeks after challenge. However, 3 of 4 test macaques had undetectable viral loads by week 12 after challenge, with the fourth macaque (3414) having only 270 copies/mL. By week 20 after challenge, all vaccinees had undetectable viral loads (figure 4A). By contrast, both control macaques maintained viral loads 110 4 copies/mL throughout follow-up ( figure 4A ). In addition, the 2 control macaques showed a complete loss of their peripheral CD4 + T cells by week 3 after challenge, whereas 3 of the vaccinated macaques maintained their CD4 + T cell counts well. Vaccinated macaque 3414 had a significant decrease in CD4 + T cell counts but no clinical signs. Of note, this macaque had the most robust immune response to the challenge (figure 4C-4E) and was able to control the infection 4 weeks later than the other vaccinees (figure 4A), despite the low CD4 + T cell counts detected throughout follow-up. One control macaque (3418) had a poor clinical course, progressed to an AIDS-like disease, and was euthanized at week 18 after challenge. The experiment was terminated at week 22 after challenge.
DISCUSSION
We report here on a long-term vaccination study in which 4 test macaques were boosted with rabies virus-VSV-G vectors expressing either SIV mac 239 Gag or SHIV 89.6P Env 2 years after initial priming with rabies virus vectors expressing the same 2 vaccine antigens. Two control macaques were similarly vaccinated with rabies virus and rabies virus-VSV-G vectors expressing no transgene. Four months after the rabies virus-VSV-G boost, macaques were challenged iv with pathogenic SHIV 89.6P . Vaccinated macaques controlled the infection, as seen by reduced viral loads, compared with those in control macaques, by mounting cellular immune responses to both SIV Gag and SHIV 89.6P Env and generating SHIV 89.6P neutralizing antibodies. Three vaccinees showed good, and 1 sufficient, retention of CD4 + T lymphocytes and showed no evidence of clinical disease from the rabies virus vaccination or SHIV challenge. By contrast, the 2 control macaques had high acute postchallenge viral loads and a near complete loss of CD4 + T cells. All 4 test macaques displayed a combination of cellular and humoral responses that resulted in undetectable levels of plasma viremia by 12 weeks after challenge in 3 of 4 macaques and only 270 copies/mL in the fourth ( figure 4C ). Of particular interest were the cellular responses to Gag and multiple epitopes in Env. Previous work in rhesus macaques has demonstrated the need for broad cellular responses to multiple epitopes to limit the selection of CTL escape mutants directed against single immunodominant epitopes [38] . The elicitation of cellular responses to multiple epitopes seen in the present study suggests that the cellular response to the challenge may be more robust and durable than those seen in Gag-only approaches.
Although statistical resolution cannot be obtained by this small sample size, the proof of concept is shown in the protection from disease in the test macaques, and the results indicate the need for future experiments with larger groups of animals. This initial report demonstrates the potential of rabies virus vectors; however, it also raises several questions that need to be addressed as the technology moves forward. The fundamental question with this approach is whether a replicating rabies virus-based vector as an HIV-1 vaccine in humans is feasible. A number of efforts have focused on developing vaccines against HIV-1 with replication-deficient viral vectors, with those based on adenovirus being the most notable. However, it is unclear whether these vectors will perform in humans as well as in monkeys because of preexisting vector immunity (for a review, see [39] ). Other vectors are in early stages of development, and their outcome is uncertain (for a review, see [40] ). For example, vectors based on alphaviruses and picornaviruses may be limited by their available coding capacity for foreign proteins. Rabies virus, however, is able to express large and multiple vaccine antigens [11] . The current HIV-1 pandemic does not allow any further delays in the development of novel vaccine approaches.
The vector most closely related to rabies virus is another Rhabdovirus, VSV, which has also been tested in the rhesus macaque system [35, 36] . One study indicated that a good level of protection requires 3 inoculations with VSV containing 3 different VSV G proteins or 1 inoculation with the VSV vector followed by a boost with recombinant modified vaccinia virus Ankara [35, 36] . The use of rabies virus, compared with VSV, may seem more risky, but there are several reasons not to discount this strategy: (1) the pathogenesis of rabies virus is better understood and more clearly defined than that of most other viral vectors; (2) recent research allows us to use vectors that are not neurotropic; (3) new mutations can be introduced into the rabies virus genome that greatly restrict the infectivity of rabies virus on neuronal cells but not on nonneural cells (G. S. Tan and M.J.S., unpublished data); and (4) attenuated rabies virus vectors administered im are not less immunogenic, as has been seen for VSV-based vectors [17, 36, 41, 42] . The ability to create rhabdoviral glycoprotein exchange vectors, such as the SPBN-IG constructs described here, provides a flexible and potentially powerful new platform for prime-boost vaccination strategies.
Additional questions with this and other emerging vaccine platforms involve study design. Can a prime-boost strategy using 2 live-recombinant viral vectors be optimized and applied to other, perhaps more relevant infection models? The low or undetectable cellular immune responses that we observed are typical for most experimental HIV-1 vaccines after initial immunization, except for macaques positive for the Mamu-A*01 MHC class I allele [4, 6, 32] . Recent work has indicated that Mamu-A*01 monkeys are more readily protected by a SIV Gagbased vaccine than macaques negative for this MHC class I allele; therefore, the use of such Mamu-A*01 monkeys for vaccine testing is now questionable [6] . None of our monkeys were Mamu-A*01 positive, yet we achieved protection comparable to that in previous reports. It remains to be seen whether the protection from disease seen in this SHIV 89.6P challenge model can be extended to other infection models in rhesus macaques. We aim to address many of these issues in future primate experiments using the SPBN-333 and SPBN-IG vectors described here.
